I don’t think novo Nordisk is

3
Comment
Favorite

MHh
11-16

I don’t think novo Nordisk is undervalued. Its antiobesity drug has been comparatively inferior compared to Eli Lilly’s and historically it also has been running into stock issues. So, I see it as inferior to Eli Lilly in both clinical performance and logistic capability which could be detrimental. Given novo Nordisk’s expected comparatively lower growth to Eli Lilly, Novo Nordisk is not undervalued and I prefer to buy a winner than a laggard.

UNH has pulled back already. However, I believe the new leadership can turn things around. It is a major player for insurance in the US and trump looks set to introduce his own ways of keeping healthcare costs affordable for the Americans though not the same strategy as Obamacare. I expect premiums to pour in as Americans depend on it to keep their healthcare costs more affordable and so I expect another rebound next year especially if recession happens.

Recently coka cola has done well too and is almost a sure win dividend stock.

# Sector Rotation: LLY Breaks $1,000, UNH Rebounds: Shift to Value Stocks?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":500615445222184,"tweetId":"500615445222184","gmtCreate":1763262283514,"gmtModify":1763268009015,"author":{"id":4091758936365950,"idStr":"4091758936365950","authorId":4091758936365950,"authorIdStr":"4091758936365950","name":"MHh","avatar":"https://static.tigerbbs.com/54b2feced9ef5dcc9e95997d1f4db280","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":1,"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.12.05","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"}}],"fanSize":847,"starInvestorFlag":false},"themes":[{"themeId":"b940b433c05d4aada5a23086a0a247b4","categoryId":"7a15628ce2174325bddc6229505e0d70","name":"Sector Rotation: LLY Breaks $1,000, UNH Rebounds: Shift to Value Stocks?","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":b940b433c05d4aada5a23086a0a247b4}&rnconfig={\"headerBarHidden\": true}","description":"DJIA, representing the traditional economy, surged strongly to notch its 16th record closing high of the year, while the tech-heavy Nasdaq Composite ended lower.\nOn Wednesday, Eli Lilly jumped to $1,017, hitting another all-time high with its market cap nearing $1 trillion! UnitedHealth has surged 5.8% over the past two days.\nAs tech stocks rotate into value plays, have you caught this sector rotation?\nWith Eli Lilly breaking new highs, is Novo Nordisk now undervalued?\nDo you believe UNH’s rebound has more room to run?\nBesides healthcare, which other value stocks are climbing lately?","image":"https://community-static.tradeup.com/news/b6852c973472c1ba359794a3c78218b3"}],"images":[],"coverImages":[],"html":"<html><head></head><body>I don’t think novo Nordisk is undervalued. Its antiobesity drug has been comparatively inferior compared to Eli Lilly’s and historically it also has been running into stock issues. So, I see it as inferior to Eli Lilly in both clinical performance and logistic capability which could be detrimental. Given novo Nordisk’s expected comparatively lower growth to Eli Lilly, Novo Nordisk is not undervalued and I prefer to buy a winner than a laggard. \n \n \n \nUNH has pulled back already. However, I believe the new leadership can turn things around. It is a major player for insurance in the US and trump looks set to introduce his own ways of keeping healthcare costs affordable for the Americans though not the same strategy as Obamacare. I expect premiums to pour in as Americans depend on it to keep their healthcare costs more affordable and so I expect another rebound next year especially if recession happens. \n \n \n \nRecently coka cola has done well too and is almost a sure win dividend stock.</body></html>","htmlText":"<html><head></head><body>I don’t think novo Nordisk is undervalued. Its antiobesity drug has been comparatively inferior compared to Eli Lilly’s and historically it also has been running into stock issues. So, I see it as inferior to Eli Lilly in both clinical performance and logistic capability which could be detrimental. Given novo Nordisk’s expected comparatively lower growth to Eli Lilly, Novo Nordisk is not undervalued and I prefer to buy a winner than a laggard. \n \n \n \nUNH has pulled back already. However, I believe the new leadership can turn things around. It is a major player for insurance in the US and trump looks set to introduce his own ways of keeping healthcare costs affordable for the Americans though not the same strategy as Obamacare. I expect premiums to pour in as Americans depend on it to keep their healthcare costs more affordable and so I expect another rebound next year especially if recession happens. \n \n \n \nRecently coka cola has done well too and is almost a sure win dividend stock.</body></html>","text":"I don’t think novo Nordisk is undervalued. Its antiobesity drug has been comparatively inferior compared to Eli Lilly’s and historically it also has been running into stock issues. So, I see it as inferior to Eli Lilly in both clinical performance and logistic capability which could be detrimental. Given novo Nordisk’s expected comparatively lower growth to Eli Lilly, Novo Nordisk is not undervalued and I prefer to buy a winner than a laggard. UNH has pulled back already. However, I believe the new leadership can turn things around. It is a major player for insurance in the US and trump looks set to introduce his own ways of keeping healthcare costs affordable for the Americans though not the same strategy as Obamacare. I expect premiums to pour in as Americans depend on it to keep their healthcare costs more affordable and so I expect another rebound next year especially if recession happens. Recently coka cola has done well too and is almost a sure win dividend stock.","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/500615445222184","repostId":0,"isVote":1,"tweetType":1,"viewCount":538,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":818,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}